BTK Inhibitors for the First-Line Treatment of CLL
BTK Inhibitors for the First-Line Treatment of CLL
Dr. Laurie Sehn discusses the first-line treatment of CLL using BTKis with Dr Jennifer Brown.
14 minutes
BTK Inhibitors for the Treatment of RR CLL
Dr. Laurie Sehn discusses the treatment of RR CLL using BTKis with Dr Jennifer Brown.
10 minutes
BTK Inhibitors for the Treatment of FL
Dr. Laurie Sehn discusses the treatment of MCL using BTKis with Dr Judith Trotman.
10 minutes
BTK Inhibitors for the Treatment of WM
Dr. Laurie Sehn discusses the treatment of WM using BTKis with Dr Judith Trotman.
12 minutes
Dr. Diego Delgado discusses how to manage patients with mixed phenotype hereditary transthyretin amyloidosis
13 minutes
Dre Geneviève Matte discutera de la prise en charge des patients atteints d'amyloïdose à transthyrétine héréditaire à phénotype mixte
13 minutes
In this episode, Dr. Michael Chu discusses the management of peripheral neuropathy with the use of brentuximab vedotin in the first-line treatment of cHL.
20 minutes
Dr Christopher Lemieux discute la PN associée au BV utilisé pour la traitement de cHL.
15 minutes
In this episode, Dr. Versha Banerji and Dr. Jennifer Brown discuss key presentations on the treatment of CLL presented at ASH.
28 minutes
Integrating Non-Covalent BTK Inhibitors in CLL:
Navigating a Rapidly Evolving Treatment Landscape
In this episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL.
18 minutes
In this episode, Dr. Versha Banerji, Dr. Sarit Assouline & Dr. Chris Hillis discuss key oral abstracts in CLL presented at EHA with an emphasis on their impact on clinical practice in Canada.
46 minutes
In this episode, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC.
25 minutes
In this episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant.
22 minutes
This episode with Dr. Normand Blais discusses the unmet treatment needs for la/mUC in the 1L setting in Canada.
11 minutes
This episode with Dr. Terence Friedlander discusses the 1L treatment of la/mUC.
15 minutes
This episode with Dr. Srikala Sridhar presents a clinical case on the treatment of la/mUC.
8 minutes
In this fourth episode, Drs Normand Blais, Terence Friedlander, and Srikala Sridhar provide their perspective in a round table discussion.
27 minutes
In this fifth episode, Dr. Thomas Powles, Dr. Normand Blais, Dr. Srikala Sridhar, and Dr. Bernie Eigl discuss the impact of data on 1L la/mUC presented at ESMO 2023.
34 minutes
Live from the CCOLD meeting in Banff, Alberta, we discuss the treatment of CLL with Dr. Laurie Sehn (BC Cancer), Dr. Matthew Davids, (Dana Farber) and Dr. Constantine Tam (University of Melbourne).
Transcript available.
31 minutes
Dr. Zain Chagla presents a summary of the TACKLE trial and a Canadian perspective on Evusheld for the treatment of COVID-19.
17 minutes
**Funding provided by BeiGene ULC, Sanofi-Aventis Canada, Seagen Canada, AstraZeneca, Merck